Teva legal chief sells 7,342 shares after exercise

Available on EDGAR 09/22/2026 - 05:02 PM EDT Accepted by SEC EDGAR 09/22/2026 - 05:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported that Interim Chief Legal Officer Brian Savage exercised stock options for 4,503 Ordinary Shares on September 18, 2026 at an exercise price of $34.70 per share and then sold a total of 7,342 Ordinary Shares in market transactions that day.

The exercised options were originally granted on March 3, 2017 and are now fully exercised, leaving no options from this grant outstanding; no Rule 10b5-1 trading plan is indicated for these transactions.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Savage Brian

Role Interim Chief Legal Officer

Sold 7,342 shs ($285K)

Approx. gross sale proceeds $285K

Approx. exercise cost $156K

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy) F2	4,503	$34.70	$156K
Exercise	Ordinary Shares	4,503	$34.70	$156K
Sale	Ordinary Shares	4,503	$38.69	$174K
Sale	Ordinary Shares F1	2,525	$39.145	$99K
Sale	Ordinary Shares	314	$38.7038	$12K

Holdings After Transaction: Stock Options (right to buy) — 0 contracts (Direct); Ordinary Shares — 8,500 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
2. F2. Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.

Key Figures

Options exercised: 4,503 shares Option exercise price: $34.70 per share Total shares sold: 7,342 shares +5 more

8 metrics

Options exercised 4,503 shares Stock options converted into Ordinary Shares on September 18, 2026

Option exercise price $34.70 per share Exercise price for the 4,503 stock options

Total shares sold 7,342 shares Ordinary Shares sold on September 18, 2026

Sale price block 1 $38.69 per share Sale of 4,503 Ordinary Shares

Weighted average sale price block 2 about $39.145 per share Sale of 2,525 shares, with individual prices from $39.14 to $39.155

Sale price block 3 about $38.7038 per share Sale of 314 Ordinary Shares

Option grant date March 3, 2017 Grant date of the exercised stock options

Option expiration date March 3, 2027 Expiration for the exercised stock options

Key Terms

Ordinary Shares, stock options, weighted average price, vested

4 terms

Ordinary Shares financial

"underlying security title is stated as Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

stock options financial

"Stock options were granted on March 3, 2017, with 1,125 vested"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vested financial

"with 1,125 vested on each of March 3, 2018, March 3, 2019"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA’s Interim Chief Legal Officer report on this Form 4?

Brian Savage, Interim Chief Legal Officer of TEVA, reported exercising stock options for 4,503 Ordinary Shares at $34.70 per share on September 18, 2026, and selling a total of 7,342 Ordinary Shares in open‑market transactions the same day.

How many TEVA (TEVA) shares did the insider sell and at what prices?

Brian Savage sold 7,342 Ordinary Shares of TEVA on September 18, 2026, including blocks at $38.69 per share, about $39.145 per share on a weighted average basis (with a range of $39.14–$39.155), and about $38.7038 per share.

What options did the TEVA insider exercise in this Form 4 filing?

He exercised stock options covering 4,503 Ordinary Shares at an exercise price of $34.70 per share. These options were granted on March 3, 2017, vested in annual tranches from 2018 through 2021, and the Form 4 shows zero options from this grant remaining afterward.

Was a Rule 10b5-1 trading plan disclosed for the TEVA insider transactions?

No. The Form 4 indicates that these transactions were not reported as being made under a Rule 10b5‑1 trading plan, and the footnotes do not describe any pre‑arranged trading arrangement.

What is the total net share change from the TEVA insider’s reported transactions?

The transactions show a net disposition of 7,342 Ordinary Shares. He acquired 4,503 shares through option exercise and then sold 7,342 shares in total, according to the transaction summary in the Form 4 data.

When do the exercised TEVA stock options expire according to the Form 4?

The stock options that were exercised for 4,503 Ordinary Shares had an expiration date of March 3, 2027, and the Form 4 reports that this option position is now fully exercised with no remaining balance from that grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savage Brian

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A STREET

(Street)

TEL AVIV 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/18/2026		M		4,503	A	$34.7	15,842	D
Ordinary Shares	09/18/2026		S		4,503	D	$38.69	11,339	D
Ordinary Shares	09/18/2026		S		2,525	D	$39.145(1)	8,814	D
Ordinary Shares	09/18/2026		S		314	D	$38.7038	8,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$34.7	09/18/2026		M			4,503	(2)	03/03/2027	Ordinary Shares	4,503	$34.7	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.14 to $39.155, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Stock options were granted on March 3, 2017, with 1,125 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020, and 1,128 vested on March 3, 2021.

	/s/ Dov Bergwerk as attorney-in-fact for Brian P. Savage	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)